The report highlights Grifols' record revenues of EUR 5,099 million, a growth of 13.6% compared to 2018. The company's key achievements for the year include the launch of new products such as Xembify®, a 20% subcutaneous immunoglobulin, and Vistaseal™™, a fibrin sealant; the publication of AMBAR clinical trial findings, which confirmed the efficacy of plasma exchange with albumin to stabilize Alzheimer's in treated patients; and the company's continued commitment to supporting global research through its Investor-Sponsored Research (ISR) program and the Grifols Chair for the Study of Cirrhosis. In 2019, Grifols also announced a strategic alliance with Shanghai RAAS to manufacture, market and develop plasma-derived products and transfusion diagnostic solutions in China.
Go back to company
Grifols SA 2019 Integrated Annual Report
Issuing Company Grifols S.A.
Report Type Integrated Report
Report Language EN
Report Filesize 11.95 MB
No. of Pages 211 pages
Reporting periodJanuary 1, 2019-December 31, 2019
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI
Materiality Assessmenttrue